CDK1 can be considered an optimal CDK target for breast cancer treatment, promoting MYC-driven transcription and tumorigenesis through mediated ubiquitin ligase activation of FBXO28 and predicting poor survival in breast cancer. This evidence concerns the gene FBXO28 and breast carcinoma.